Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Lebbeke – page 67

2 122 clinical trials in Lebbeke, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Lebbeke at a glance
2 122
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

2 122 trials in Lebbeke

Open in trial search

Malignant peritoneal neoplasm+1

Not yet recruiting

Maintenance therapy with raludotatug deruxtecan alone or with bevacizumab versus standard care in patients with newly diagnosed advanced ovarian cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Lupus nephritis+2

Not yet recruiting

Phase 2 Open‑Label Trial Assessing Safety and Efficacy of Nebaprubart in Adults with IgA‑Mediated Renal Diseases

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:JJP BIOLOGICS Sp. z o.o.

Colitis ulcerative+1

Not yet recruiting

Study of ABBV-701 and Risankizumab Combination vs Monotherapy in Adults with Moderately to Severely Active Crohn’s Disease or Ulcerative Colitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Colon cancer

Not yet recruiting

Neoadjuvant Pembrolizumab and Porustobart for Resectable pMMR/MSS Colon Cancer: A Phase 2 Study of Efficacy and Safety in Eligible Patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Solstice Oncology Inc.

Pulmonary hypertension

Not yet recruiting

Phase 3 Trial Evaluating Inhaled Mosliciguat for Safety, Efficacy, and Exercise Capacity in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Mosliciguat
  • Sponsor:Pulmovant Inc.

Colitis ulcerative+1

Not yet recruiting

Study of risankizumab plus anti‑α4β7 integrin antibody versus each alone in adults with moderately to severely active Crohn’s disease or ulcerative colitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Endometrial cancer

Not yet recruiting

Maintenance Treatment Study of gsk5733584 with dostarlimab or pembrolizumab in patients with mismatch repair proficient advanced or recurrent endometrial cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

COVID-19+1

Not yet recruiting

Safety and immune response of investigational mRNA vaccine GSKVX000000078664 versus drug combination in adults with flu and COVID-19

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Elasomeran
  • Sponsor:GlaxoSmithKline Biologicals

Schizophrenia

Not yet recruiting

A study to evaluate the effect of xanomeline tartrate and trospium chloride on cognitive impairment in adults with schizophrenia.

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Trospium Chloride
  • Sponsor:European Group for Research in Schizophrenia Stichting

Immune response and safety of revaccination with respiratory syncytial virus glycoprotein F recombinant vaccine adjuvanted with AS01E in older adults

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years · Healthy volunteers
  • Substances:GSKVx000000017064
  • Sponsor:GlaxoSmithKline Biologicals

Cardiac failure+5

Not yet recruiting

Safety and Early Effectiveness of Intramyocardial Cardiac Atrial Stem Cells Compared with Sodium Chloride in Patients with Advanced Ischemic Heart Failure

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:CASCS
  • Sponsor:CASC8

Partial seizures

Not yet recruiting

Phase 3 Randomized Study of RAP-219 to Reduce Seizure Frequency in Adults with Focal Epilepsy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Rapport Therapeutics Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Lebbeke

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical research focusing on proton pump inhibitor (PPI) medication management in patients with chronic digestive conditions.

  • Functional Dyspepsia Management
  • Heartburn Treatment Optimization
  • Reflux Control Strategies

This study explores alternative approaches to managing digestive disorders, comparing on-demand PPI use and alginate therapy with traditional stepped-down treatment methods.

02 Primary Care Innovation

Ground-breaking research in medication deprescribing strategies, aimed at optimizing long-term medication use in primary care settings.

  • Medication Optimization
  • Patient-Centered Care
  • Evidence-Based Deprescribing

The research evaluates three distinct approaches to reducing unnecessary long-term medication use while maintaining therapeutic effectiveness.

03 Therapeutic Strategy Research

Investigation into alternative treatment approaches for common digestive conditions, focusing on patient safety and optimal outcomes.

  • Comparative Treatment Analysis
  • Long-term Medication Management
  • Quality of Life Assessment

This clinical trial aims to establish evidence-based guidelines for medication reduction while maintaining symptom control.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.